宁夏英力特化工股份有限公司 第九届董事会独立董事专门会议第十次会议审核意见 宁夏英力特化工股份有限公司（以下简称公司）独立董事于 2025 年 7 月 29 日以通讯形式召开了第九届董事会独立董事专门会议第十 次会议，会议应出席独立董事 3 人，实际出席独立董事 3 人。根据《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》等法律法规、规范性文件及公司 独立董事工作制度等有关规定，会议审议通过了《关于开展 2025 年 度 PVC 期货套期保值业务的议案》，全体独立董事同意将《关于开展 2025 年度 PVC 期货套期保值业务的议案》提交公司第九届董事会第 四十次（临时）董事会审议。经审阅会议材料并与相关人员沟通，独 立董事本着独立客观的原则，发表审核意见如下： 王斌 卢万明 赵恩慧 2025 年 7 月 29 日 公司已就开展商品套期保值业务制定了比较完善的套期保值管 理制度，建立了健全的组织机构，明确了业务操作流程、审批流程、 报告、保密等规定，能够保证业务的规范实施；公司使用自有资金开 展 PVC 期货套期保值业务及相关审批程序符合国家相关法律法规及 ...

宁夏英力特化工股份有限公司 关于增补提名第九届董事会非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 近日，宁夏英力特化工股份有限公司（以下简称公司）收到田少 平先生的辞职报告，因工作调整原因辞去公司董事、董事长、董事会 专门委员会委员及主任委员职务，辞职后田少平先生不在公司担任任 何职务，田少平先生的辞职报告自送达董事会时生效。因实施股权激 励计划，截至本公告日，田少平先生尚持有公司 15,345 股限制性股 票，占公司总股本的 0.0051%，该部分限制性股票公司已于 2025 年 5 月履行完毕回购注销程序，正在办理回购注销事宜，田少平先生承诺 遵守上市公司董事所持公司股份管理的相关规定。 为保证公司董事会规范运行，经股东单位国能英力特能源化工集 团股份有限公司推荐，董事会提名委员会资格审查，提名李勇先生为 公司第九届董事会非独立董事候选人。公司于2025年8月5日召开第九 届董事会第四十次（临时）会议，审议通过了《关于增补提名第九届 董事会非独立董事的议案》，同意提名李勇先生为公司第九届董事会 非独立董事候选人，并同意将《关于补选第九届 ...

关于开展 2025 年度 PVC 期货套期保值业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.交易目的：宁夏英力特化工股份有限公司（以下简称公司）充 分利用期货市场的套期保值功能，规避主营产品价格波动风险，维持 产品价格的相对稳定，保障公司经营稳定。 证券代码：000635 证券简称：英力特 公告编号：2025-048 宁夏英力特化工股份有限公司 （一）交易的必要性及可行性 公司为从事 PVC 生产与销售的企业。聚氯乙烯价格不仅受上游原 1 材料成本波动、国内外主要装置产能投放及开工率等基本面因素影响 外，还受到宏观及金融因素影响，长期以来价格波动频繁。作为公司 主营产品，PVC 市场波动对公司经营有较大影响，公司通过大连商品 交易所期货合约开展交易，以套期保值为目的，不做投机性交易，所 有交易行为均以正常生产经营为基础，以具体经营业务为依托，以实 现套期保值效果，通过期货合约的开仓及平仓操作，可有效的实现对 冲 PVC 价格波动风险的效果。公司开展 PVC 期货套期保值业务可以规 避价格不利波动对公司经营产生的风险，保证产品价 ...

上述联系方式自本公告之日起正式启用。除上述信息变更外， 公司注册地网址、电子邮箱等其他联系方式均保持不变。 关于变更投资者热线信息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 宁夏英力特化工股份有限公司（以下简称公司）根据办公需 要，对投资者热线进行了调整，为确保与投资者保持密切沟通，现 将投资者热线信息公告如下： | 项目 | 调整前 | 调整后 | | --- | --- | --- | | 投资者热线 | 0952-3689323 | 0952-3820080 | | 传真 | 0952-3689589 | 0952-3820083 | 证券代码：000635 证券简称：英力特 公告编号：2025-050 宁夏英力特化工股份有限公司 宁夏英力特化工股份有限公司董事会 2025 年 8 月 6 日 1 ...

证券代码：000635 证券简称：英力特 公告编号：2025-046 宁夏英力特化工股份有限公司 第九届董事会第四十次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2.以8票赞成，0票反对，0票弃权，审议通过了《关于开展2025 年度PVC期货套期保值业务的议案》。 2.本次会议于 2025 年 8 月 5 日以通讯形式召开。 3.本次会议应出席董事8人，实际出席董事8人。 4.本次会议由副董事长眭明忠先生主持，部分高级管理人员列席。 5.本次会议的召开符合有关法律法规和《公司章程》等规定。 二、董事会会议审议情况 1.以8票赞成，0票反对，0票弃权，审议通过了《关于增补提名 第九届董事会非独立董事的议案》； 近日，田少平先生因工作调整原因辞去公司董事、董事长及董事 会专门委员会委员及主任委员职务。为保证公司董事会规范运行，经 股东单位国能英力特能源化工集团股份有限公司推荐，公司董事会提 名委员会资格审查，第九届董事会第四十次（临时）会议审议通过了 《关于增补提名第九届董事会非独立董事的议案》，同意提名李勇先 生 ...

英力特股价最新报9.11元，较前一交易日下跌1.94%。盘中最高触及9.28元，最低下探至9.01元，成交量 为66968手，成交金额达0.61亿元。 该公司属于化学原料行业，业务涉及宁夏地区，具有央国企改革和西部大开发等属性。英力特主要从事 化工产品的生产和销售业务。 公司在互动平台回应投资者时表示，产品价格采取随行就市的调整策略。2025年上半年度具体经营业绩 将在后续发布的半年度报告中披露。 7月29日主力资金净流出350.43万元，占流通市值的0.13%。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

Performance Forecast - The company expects a net loss attributable to shareholders of 148 million yuan for the current reporting period, compared to a loss of 123.56 million yuan in the same period last year, representing a year-on-year decline of 19.78% [1] - The loss after deducting non-recurring items is projected to be 151.6 million yuan, compared to a loss of 126.73 million yuan in the previous year, reflecting a decline of 19.63% [1] - Basic earnings per share are expected to be a loss of 0.49 yuan per share, compared to a loss of 0.41 yuan per share in the same period last year [1] - The company's operating revenue is estimated at 866.97 million yuan, down from 963.25 million yuan in the previous year [1] Communication with Auditors - The financial data related to this performance forecast has not been audited by registered accountants, but the company has communicated with the auditing firm regarding the performance forecast, and there are no discrepancies between the company and the auditors [1] Reasons for Performance Changes - The net profit attributable to shareholders of the listed company is expected to show an increased loss compared to the previous year [1]

[Core Performance Indicators Forecast](index=1&type=section&id=Item%20I.%20Current%20Period%20Performance%20Forecast) The company anticipates a widened net loss for the first half of 2025, with attributable net profit projected at a loss of 148 million yuan and operating revenue at 867 million yuan - The performance forecast covers the period from January 1, 2025, to June 30, 2025[3](index=3&type=chunk) Key Financial Indicators Comparison | Item | Current Period (Estimated) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | **Loss: 148.00 million yuan** | Loss: 123.56 million yuan | | Year-on-Year Change | -19.78% | - | | **Net Profit After Non-Recurring Items** | **Loss: 151.60 million yuan** | Loss: 126.73 million yuan | | Year-on-Year Change | -19.63% | - | | **Basic Earnings Per Share** | **Loss: 0.49 yuan/share** | Loss: 0.41 yuan/share | | **Operating Revenue** | 866.97 million yuan | 963.25 million yuan | [Communication with Accounting Firm](index=1&type=section&id=Item%20II.%20Communication%20with%20Accounting%20Firm) The company has pre-communicated the performance forecast with its annual report auditing firm, confirming no disagreements, though the data remains unaudited - The financial data in this performance forecast has not been audited by a certified public accountant[3](index=3&type=chunk) - The company has pre-communicated the forecast content with the annual report auditing accounting firm, with no disagreements between the parties[3](index=3&type=chunk) [Analysis of Performance Change Attribution](index=1&type=section&id=Item%20III.%20Explanation%20of%20Performance%20Change%20Reasons) The primary reason for the widened loss in the first half of 2025 is the year-on-year decline in sales prices of the company's main products, PVC and EPVC - The decline in performance is primarily attributed to the year-on-year decrease in sales prices of main products, PVC and EPVC[4](index=4&type=chunk) - The price decline led to a year-on-year widening of the net loss attributable to shareholders of the listed company[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=Item%20IV.%20Risk%20Warning) The company advises investors that this performance forecast is a preliminary estimate by the financial department, subject to uncertainty, with final data to be confirmed in the 2025 semi-annual report - This performance forecast is a preliminary estimate by the company's financial department and is subject to uncertainty[6](index=6&type=chunk) - Investors are advised to be aware of investment risks, as specific financial data will be based on the company's 2025 semi-annual report[6](index=6&type=chunk)

Core Viewpoint - The company, Yinglite (000635), is expected to report a net loss attributable to shareholders of 148 million yuan for the period from January 1, 2025, to June 30, 2025, representing a 19.78% decrease compared to the same period last year [1] Financial Performance - The projected net profit loss excluding non-recurring gains and losses is 152 million yuan, a 19.63% decline from the previous year's loss of 127 million yuan [1] - The basic earnings per share are expected to be a loss of 0.49 yuan per share [1] - Estimated operating revenue is 867 million yuan, down from 963 million yuan in the same period last year [1]

Market Overview - The market experienced a strong upward trend, with the Shanghai Composite Index stabilizing above 3500 points. Real estate stocks surged in the afternoon, with several stocks such as Huaxia Happiness and Deep Deep Housing A hitting the daily limit. Major financial stocks continued to perform well, with the four major banks reaching historical highs. The photovoltaic sector also saw a rebound, particularly in the organic silicon segment, with multiple stocks hitting the daily limit. Overall, over 2800 stocks in the Shanghai and Shenzhen markets rose, with a total transaction volume of 1.51 trillion yuan [1]. Real Estate Sector - The real estate sector saw significant gains, with stocks like Sifang New Materials and Yucheng Development hitting the daily limit. The National Development and Reform Commission emphasized increasing investment in new urbanization, which catalyzed the market. Additionally, around 20 cities, including Chongqing and Shenyang, have supported and optimized the "commercial to public" policy this year [4][5]. - According to the China Index Academy, to alleviate insufficient effective demand, some cities may further relax purchase and loan restrictions, while also accelerating the construction of affordable housing and optimizing land supply structures to promote a stable and healthy real estate market [5]. Pharmaceutical Sector - The pharmaceutical sector remained active, with stocks like Saily Medical and Lianhuan Pharmaceutical hitting the daily limit. Merck announced a $10 billion acquisition of Verona Pharma to enhance its COPD treatment product line. The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, which include 16 initiatives to strengthen support for innovative drug research and development [6][7]. - The trend of Chinese innovative drugs going global is expected to enhance profitability and market space, leading to improved industry valuation levels. The adjustment plan for the national medical insurance directory and commercial insurance innovative drug directory is anticipated to be implemented in November [8]. Hydrogen Energy Sector - The hydrogen energy sector showed strong performance, with stocks like Huaguang Huaneng and Tianwo Technology hitting the daily limit. The emphasis on developing hydrogen energy as part of a new energy system was highlighted during a recent inspection by the General Secretary in Shanxi [9][10]. - The strategic position of hydrogen energy has been established, with local policies supporting its development. The renewable energy green hydrogen production capacity is expected to reach over 400,000 tons by 2025 in the Sanbei region. The construction of hydrogen pipelines is also entering a capital-intensive phase, with major state-owned enterprises as primary investors [10]. Other Notable Sectors - Other sectors such as consumer goods and finance showed localized activity, while military and digital currency high-priced stocks experienced declines [11]. - The market is also witnessing a focus on performance as the mid-year reporting period approaches, with expectations for continued improvement in the performance of innovative drugs and their supply chains [8].